MARKET

SGMT

SGMT

Sagimet Biosciences Inc.
NASDAQ
3.310
+0.050
+1.53%
After Hours: 3.470 +0.16 +4.83% 19:48 05/12 EDT
OPEN
3.360
PREV CLOSE
3.260
HIGH
3.480
LOW
3.270
VOLUME
538.20K
TURNOVER
--
52 WEEK HIGH
7.38
52 WEEK LOW
1.730
MARKET CAP
106.57M
P/E (TTM)
-1.8643
1D
5D
1M
3M
1Y
5Y
1D
Sagimet Biosciences price target lowered to $25 from $30 at Oppenheimer
TipRanks · 9h ago
Sagimet Biosciences, Inc. Class A (SGMT) Receives a Buy from TD Cowen
TipRanks · 15h ago
Weekly Report: what happened at SGMT last week (0505-0509)?
Weekly Report · 17h ago
Sagimet Biosciences Reports Q1 2025 Financial Results
TipRanks · 2d ago
JonesTrading Keeps Their Buy Rating on Sagimet Biosciences, Inc. Class A (SGMT)
TipRanks · 3d ago
Sagimet Biosciences reports Q1 results
Seeking Alpha · 4d ago
Sagimet Biosciences, Inc. Reports Financial Results for the Quarter Ended March 31, 2025
Press release · 4d ago
Sagimet Biosciences reports Q1 EPS (56c), consensus (69c)
TipRanks · 4d ago
More
About SGMT
More
Sagimet Biosciences Inc. is a clinical-stage biopharmaceutical company developing fatty acid synthase (FASN) inhibitors that are designed to target dysfunctional metabolic and fibrotic pathways in diseases resulting from the overproduction of the fatty acid, palmitate. The Company's lead drug candidate, denifanstat, is an oral, once-daily pill and selective FASN inhibitor in development for the treatment of metabolic dysfunction associated steatohepatitis (MASH). Denifanstat has been granted Breakthrough Therapy designation by the FDA for the treatment of non-cirrhotic MASH with moderate to advanced liver fibrosis. The Company is also exploring the use of its FASN inhibitors, which include denifanstat and its pipeline product candidate, TVB-3567, in acne and in select forms of cancer. Denifanstat is being tested in China by its license partner, Ascletis BioScience Co. Ltd., for moderate to severe acne vulgaris and recurrent glioblastoma multiforme in combination with bevacizumab.
Recently
Symbol
Price
%Change

Webull offers Sagimet Biosciences Inc stock information, including NASDAQ: SGMT real-time market quotes, financial reports, professional analyst ratings, in-depth charts, corporate actions, SGMT stock news, and many more online research tools to help you make informed decisions. Trade stocks for 0 commission and 0 contract fees on the web version for easy and convenient access, or download the Webull app and trade on the go.

You can practice and explore trading SGMT stock methods without spending real money on the virtual paper trading platform.